BioSpace News Archive

NRx Pharmaceuticals, Inc. today reported the recommendations of an independent Data Safety Monitoring Board (DSMB) which reviewed the safety findings of the first fifty enrolled participants in the Company’s phase 2 clinical trial of NRX-101 for the treatment of Severe Bipolar Depression and Subacute Suicidal Ideation or Behavior (www.clinicaltrials.gov NCT NCT03395392).

Quest Diagnostics Incorporated (NYSE: DGX), the world’s leading provider of diagnostic information services, announced today financial results for the fourth quarter and full year ended December 31, 2022.

Tango Therapeutics , Inc. today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in the following upcoming investor conferences in February.

First Wave BioPharma, Inc. today announced that the first patient was screened for the Phase 2 SPAN clinical trial investigating an enhanced enteric microgranule delivery formulation of adrulipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF).

ProSciento, Inc., a leading specialty clinical research organization (CRO) exclusively focused on metabolic diseases, today announced the appointment of David Sockolof to the role of Chief Financial Officer (CFO).

JMIR AI is focused on the intersection between clinical neuroscience and technology to prevent, diagnose, and treat neurological disorders.

Repare Therapeutics Inc. today announced that members of its senior management team will participate at two investor conferences in February and March.

Verastem Oncology today outlined key strategic priorities and upcoming catalysts to support its lead compound RAF/MEK clamp avutometinib in RAS pathway-driven cancers.

Rockwell Medical, Inc. announced that the Company signed a three-year, multi-million dollar per annum product purchase agreement with the largest non-profit dialysis provider in the United States.

Mednow Inc. (“Mednow” or the “Company”) (TSXV: MNOW) (OTCQX: MDNWF) announced today the launch of its enhanced Virtual Diabetes Management program, an end-to-end digital diabetes management solution, to enable convenient on-demand access to Dexcom G6 (NASDAQ: DXCM) real-time continuous glucose monitoring (rtCGM) supplies and personalized diabetes care services.